Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Sep 26.
doi: 10.1007/s40264-025-01617-7. Online ahead of print.

Comment on: Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study

Chien-Hsiang Weng  1   2 , Philip A Chan  3 , Joseph Magagnoli  4 , Charles L Bennett  4
Affiliations
Comment

Comment on: Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study

Chien-Hsiang Weng et al. Drug Saf. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of Interest: Authors have nothing to disclose related to the submitted work. Ethics Approval: Not applicable as this is a letter to the editor providing comments on a published study. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Availability of Data and Material (data transparency): Not applicable. Code Availability: Not applicable. Authors' Contributions: CHW: Conceptualization, investigation, methodology, writing—original draft, review & editing; PAC: Conceptualization, investigation, methodology, writing—review & editing; JM: Conceptualization, investigation, methodology, resources, writing—review & editing; CLB: Conceptualization, investigation, writing—review & editing. All authors read and approved the final version.

Comment on

References

    1. Titus J, Katukuri V, Boktor M, Mansi IA. Association of GLP1-receptor agonists with risk of hepatocellular carcinoma: a retrospective cohort study. Drug Saf. 2025;48:1089–101.
    1. Hsu WH, Sue SP, Liang HL, Tseng CW, Lin HC, Wen WL, et al. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a nationwide study in Taiwan. Front Public Health. 2021;9:711723. - DOI - PubMed - PMC
    1. Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–41. - DOI - PubMed
    1. Shim JJ, Kim JW, Kim BH. Risk of hepatitis B virus-related hepatocellular carcinoma development is much higher in Koreans than in Taiwanese. Korean J Intern Med. 2017;32(5):940–2. - DOI - PubMed - PMC
    1. Shabil M, Khatib MN, Ballal S, Bansal P, Tomar BS, Ashraf A, et al. Risk of hepatocellular carcinoma with glucagon-like peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024;24(1):246. - DOI - PubMed - PMC

LinkOut - more resources